Showing papers in "Ophthalmology in 2015"

TL;DR: Five-year results suggest focal/grid laser treatment at the initiation of intravitreal ranibizumab is no better than deferring laser treatment for ≥24 weeks in eyes with DME involving the central macula with vision impairment.

TL;DR: In both VISTA and VIVID, the 52-week visual and anatomic superiority of IAI over laser control was sustained through week 100, with similar efficacy in the 2q4 and 2q8 groups.

TL;DR: The response to anti-VEGF drugs in DME is not as robust as in proliferative diabetic retinopathy, and many patients with DME do not show complete resolution of fluid despite multiple intravitreal injections.

TL;DR: Using OCTA allows the clinician to visualize CNV noninvasively and may provide a method for identifying and guiding treatment of CNV and the specificity of C NV detection on OCTA compared with FA seems to be high.

TL;DR: Myopia is becoming more common in Europe; although education levels have increased and are associated with myopia, higher education seems to be an additive rather than explanatory factor.

TL;DR: Bvaczumab and ranibizumab had equivalent effects on visual acuity at 1 year when administered according to a treat-and-extend protocol, and the visual acute results were comparable to those of other clinical trials with monthly treatment.

TL;DR: Each of the 11 commonly cited barriers to optimal glaucoma medication adherence was important to at least 30% of surveyed patients with poor adherence, with most identifying multiple barriers to adherence.

TL;DR: The VIBRANT trial as discussed by the authors showed that 2 mg intravitreal aflibercept injection (IAI) compared with grid laser was effective in controlling macular edema.

TL;DR: This translational science review focuses on studies performed in animal models of OIR representative of human ROP and highlights several areas: mechanisms for aberrant growth of blood vessels into the vitreous rather than into the retina through over-activation of VEGF receptor 2 signaling, the importance of targeting different cells in the retina to inhibit aberrant angiogenesis and promote physiologic retinal vascular development.

TL;DR: In this article, a volumetric optical coherence tomography angiography (OCTA) was used to noninvasively visualize alterations in the retinal and choriocapillaris (CC) vasculatures in normal subjects and patients with nonexudative age-related macular degeneration with geographic atrophy.

TL;DR: The TREX neovascular AMD management strategy used in this prospective, randomized, controlled trial resulted in visual and anatomic gains comparable with those obtained with monthly dosing.

TL;DR: The 3-year results of the Argus II trial support the long-term safety profile and benefit of theArgus II System for patients blind from RP and the first and only retinal implant to have both approvals.

TL;DR: The continued movement away from trabeculectomy and toward alternative intraocular pressure-lowering procedures highlights the need for well-designed clinical trials comparing these procedures.

TL;DR: The SMILE procedure has a less pronounced impact on the ocular surface and corneal innervation compared with LASIK, further reducing the incidence of dry eye disease and subsequent degradation in quality of life after refractive surgery.

TL;DR: In this paper, the authors determined whether peripheral diabetic retinopathy (DR) lesions identified on ultrawide field (UWF) imaging are associated with increased DR progression and progression to PDR.

TL;DR: In this paper, the long-term outcomes of eyes with neovascular age-related macular degeneration (AMD) starting treatment with vascular endothelial growth factor (VEGF) inhibitors at least 5 years earlier were analyzed.

TL;DR: The number of corneal transplants increased from 44,277 in 2005 to 46,513 in 2014 as discussed by the authors, with a significant shift in preferred keratoplasty techniques over the past decade with a wide adoption of new LK techniques.

TL;DR: In this paper, the authors investigated baseline predictors of month 24 best-corrected visual acuity (BCVA) and central foveal thickness (CFT) in patients with diabetic macular edema (DME) treated monthly with ranibizumab or sham.

TL;DR: Compared with DSAEK, DMEK provided better visual recovery and comparable 6-month ECL, and patients with pre-existing ocular comorbidity that impacted visual potential such as macular degeneration, amblyopia, advanced glaucoma, and other optic neuropathies were excluded from the analysis of visual acuity.

TL;DR: In comparison with earlier endothelial keratoplasty techniques, DMEK may consistently give higher visual outcomes and faster visual rehabilitation and may become the first choice of treatment in corneal endothelial disease.

TL;DR: Evidence is provided that, at least in the initial months of lens wear, overnight orthokeratology contact lens wear inhibits axial eye growth and myopia progression compared with conventional GP lenses.

TL;DR: Both IVB and PRP are effective treatment options for type 1 ROP with low complication rates and IVB was associated with less myopia than PRP, although longer follow-up was available for PRP.

TL;DR: Following a standardized protocol, the evaluation of UWF FA for NPA and NPI is reproducible and both parameters are correlated highly with the presence of PPLs and DR severity.

TL;DR: Phacoemulsification typically results in small, moderate, and marked reductions of IOP and medications for patients with POAG, PXG, and PACG, respectively, and using 1 to 2 medications before surgery.

TL;DR: Diabetes, diabetes duration, and fasting glucose levels were associated with a significantly increased risk of glaucoma, and diabetes and fasting glycemic levels wereassociated with slightly higher IOP.

TL;DR: Intraocular pressure was clinically and statistically significantly lower at 2 years in the Hydrus plus CS group compared with the CS alone group, with no differences in safety.

TL;DR: Ranibizumab, as administered to patients with DME for 12 to 36 months in these studies, can both improve DR severity and prevent worsening, and prolonged delays in initiation of ranibizuab therapy may limit this therapeutic effect.

TL;DR: In this article, the authors evaluated intravitreal aflibercept 2 mg in patients with myopic choroidal neovascularization (CNV) in patients aged ≥18 years with high myopia (≤−6.0 diopters or axial length of ≥26.5 mm).

TL;DR: The subretinal pigment epithelium lesion underlying PED appears to be the primary indicator for progressive disease activity, whereas secondary cystoid degeneration is the most relevant imaging marker for visual function.

TL;DR: Baseline severity, magnitude, and rates of change in BVF sensitivity were associated with longitudinal changes in QoL of glaucoma patients, and assessment of longitudinal visual field changes may help to identify patients at greater risk for developing disability from the disease.